Title |
Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside
|
---|---|
Published in |
Autoimmunity Highlights, August 2014
|
DOI | 10.1007/s13317-014-0058-y |
Pubmed ID | |
Authors |
D. Squatrito, G. Emmi, E. Silvestri, L. Ciucciarelli, M. M. D’Elios, D. Prisco, L. Emmi |
Abstract |
Systemic lupus erythematosus (SLE) is considered an autoimmune disease with multiorgan involvement. Many advances have been made during the last decade regarding inflammatory pathways, genetic and epigenetic alterations, adaptive and innate immune system mechanisms specifically involved in SLE pathogenesis. Apoptosis has been proposed as an important player in SLE pathogenesis more than a decade ago. However, only recently new key apoptotic pathways have been investigated and the link between apoptotic debris containing autoantigens, innate immunity and ongoing inflammation has been further elucidated. Better understanding of cellular mechanisms and involved cytokines contributed to the development of new biological drugs specifically addressed for SLE therapy. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Venezuela, Bolivarian Republic of | 1 | 25% |
France | 1 | 25% |
Unknown | 2 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 75% |
Scientists | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 77 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 14 | 18% |
Student > Master | 13 | 17% |
Student > Ph. D. Student | 9 | 12% |
Other | 8 | 10% |
Student > Doctoral Student | 5 | 6% |
Other | 14 | 18% |
Unknown | 14 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 43% |
Agricultural and Biological Sciences | 13 | 17% |
Biochemistry, Genetics and Molecular Biology | 8 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Immunology and Microbiology | 2 | 3% |
Other | 1 | 1% |
Unknown | 16 | 21% |